Clinical trials: Methylphenidate
ADHD
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
The study is a multicenter, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03292952
- Testing
- KP415 oral capsule
- Where
- 5 sites in United States
- Volunteers
- 155 people
- Sponsor
- Zevra Therapeutics
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Breast Cancer, Fatigue
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl (Concerta) can help to control fatigue in patients with breast, gastrointestinal, lymphoma, myeloma or lung cancer who are going through…
- Conditions
- Breast Cancer, Fatigue, Gastrointestinal Cancer
- Trial name
- NCT00516269
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Alcohol Use Disorder
Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
This study will evaluate the behavioral effects of alcohol during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.
- Trial name
- BED[IN]:36 (NCT03575403)
- Testing
- Alcohol, Duloxetine (60 MG), Methylphenidate
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Craig Rush
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
The purpose of this study is to a) assess the efficacy of omega-3 fatty acids in the treatment of Deficient Emotional Self-Regulation (DESR) among stimulant treated Attention Deficit Hyperactivity Disorder (ADHD) adults, b)…
- Trial name
- NCT01399827
- Testing
- ADHD Medication, Omega-3 Fatty Acids
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Multiple Sclerosis
Methylphenidate to Improve Balance and Walking in MS
Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis tachycardia syndrome and narcolepsy.
- Trial name
- NCT01896700
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Oregon Health and Science University
Healthy
A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults
This is a double-blind, randomized, placebo-controlled, five-period crossover study to examine the likability of a repeated administration of immediate release methylphenidate hydrochloride (IR-MPH 40 mg) and OROS®-MPH (CONCERTA®…
- Trial name
- NCT00302458
- Testing
- OROS-Methylphenidate, Immediate Release Methylphenidate
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
ALL, Childhood, Leukemia, Lymphoblastic
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention…
- Conditions
- ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1
- Trial name
- NCT01100658
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Minnesota
Attention Deficit Disorder With Hyperactivity
Treatment of Severe Childhood Aggression (The TOSCA Study)
This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00796302
- Testing
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- Michael Aman
Epilepsy, Cognitive Deficits
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate (MPH) has long been used to improve attention and cognitive difficulties associated with ADHD, including in children with ADHD and epilepsy (Torres et al., 2008).
- Conditions
- Epilepsy, Cognitive Deficits, Attention Deficits
- Trial name
- NCT02178995
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Kimford Jay Meador
Obesity, Apathy
Role of Apathy in the Effectiveness of Weight Loss Interventions
The purpose of this study is to determine whether treating apathy with methylphenidate or medical Crisis counselling will increase adherence to weight loss programs thereby increasing their effectiveness
- Trial name
- NCT00548652
- Testing
- MOVE, medical crisis councelling, methyphenidate
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- VA Nebraska Western Iowa Health Care System
Attention Deficit Hyperactivity Disorder
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
This pilot study seeks to evaluate initial evidence for the effect of L-methylfolate supplementation to OROS-Methylphenidate pharmacotherapy on ADHD symptoms and associated features in adults with ADHD, as well as tolerability of…
- Trial name
- NCT01853280
- Testing
- L-methylfolate, OROS-Methylphenidate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Massachusetts General Hospital
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer
This randomized phase II trial studies how well cognitive behavioral therapy and multimodal therapy works in treating sleep disturbance in patients with cancer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
- Trial name
- NCT01628029
- Testing
- Counseling, Methylphenidate Hydrochloride, Phototherapy
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
ADHD, Attention Deficit Hyperactivity Disorder
Study of Medication Patch to Treat Children Ages 6-12 With ADHD
The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch.
- Trial name
- NCT00586157
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Cognition Disorder, Attention Deficit Disorder
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Deficits in memory, attention, cognitive, and executive functions are the most common disabilities after traumatic brain injury (TBI).
- Conditions
- Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
- Trial name
- DAPET-TBI (NCT02225106)
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV
Attention-Deficit Hyperactivity Disorder
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
- Trial name
- NCT01323192
- Testing
- JNS001
- Where
- 30 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Janssen Pharmaceutical K.K.
Attention Deficit/Hyperactivity Disorder
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P02 (NCT05721235)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 123 people
- Sponsor
- Corium, Inc.
Attention Deficit Hyperactivity Disorder
Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Children with Attention Deficit Hyperactivity Disorder (ADHD) have numerous areas of neuropsychological dysfunction including response inhibition, working memory, and attention.
- Trial name
- NCT01238822
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Disorder With Hyperactivity
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine the effectiveness of behavioral treatment, drug treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00050622
- Testing
- Methylphenidate 0.15 mg/kg, Low-Intensity BMOD, Methylphenidate 0.3 mg/kg
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Florida International University